Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Confo Therapeutics N V currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners. The prosecution is spread across 2 distinct art units, which indicates that the company's filings are being reviewed by different specialized groups within the patent office.
The busiest examiner, HABTE, KAHSAY, is responsible for 1 pending office action. This count of 1 pending action matches the workload of the other of the 2 distinct examiners. With 2 pending office actions in total, the portfolio is evenly split between the assigned officials. The 2 distinct art units suggest that each of the 2 pending office actions is being evaluated in a different technical context.
Practitioners should observe that the Biotechnology & Pharmaceuticals applications are not concentrated under a single examiner or art unit. Instead, the 2 distinct examiners provide multiple perspectives across 2 distinct art units. This distribution may lead to different examination experiences for the 2 pending office actions. The current data shows a decentralized prosecution front for Confo Therapeutics N V.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293160 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | HABTE, KAHSAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17607334 | CHIMERIC PROTEINS AND METHODS TO SCREEN FOR COMPOUNDS AND LIGANDS BINDING TO GPCRS | REYNOLDS, FRED H | 98d overdue |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18293160 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | — | Pending | Jan 29, 2024 |
| 17607334 | CHIMERIC PROTEINS AND METHODS TO SCREEN FOR COMPOUNDS AND LIGANDS BINDING TO GPCRS | REYNOLDS, FRED H | 1658 | §112 | Final Rejection | 98d overdue | Pending | Oct 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial